Payment overview · 2025
General Payments
$1,351.99
89 reported records · 10 companies
Healthcare provider profile · identity verified
Michael Edward Joseph, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · JOPLIN, MO · NPI 1902919178
Verified facts
What the public records show
CMS Open Payments records show Michael Edward Joseph, MD received $1,351.99 in general payments during 2025 across 89 reported records.
Amgen Inc. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Simponi Aria by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $431.25 | 31.9% | 38 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $318.41 | 23.6% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $206.01 | 15.2% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $132.37 | 9.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.43 | 5.8% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $54.77 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.79 | 3.2% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.01 | 2.6% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $30.90 | 2.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.05 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,351.99 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $170.21 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $162.33 | 8 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $154.70 | 9 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $148.20 | 10 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $115.03 | 6 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $78.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.80 | 13 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $66.80 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $65.81 | 7 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $54.77 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.91 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $42.30 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $35.64 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $34.69 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $25.63 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 902 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 803 | 172 |
| Potassium Chloride | Potassium Chloride | 600 | 212 |
| Methotrexate | Methotrexate Sodium | 521 | 101 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 476 | 105 |
| Gabapentin | Gabapentin | 432 | 91 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 421 | 246 |
| Celecoxib | Celecoxib | 387 | 90 |
| Cefdinir | Cefdinir | 383 | 249 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 337 | 47 |
| Omeprazole | Omeprazole | 330 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 80 |
| Meloxicam | Meloxicam | 323 | 97 |
| Montelukast Sodium | Montelukast Sodium | 258 | 62 |
| Alprazolam | Alprazolam | 245 | 36 |
| Azithromycin | Azithromycin | 240 | 136 |
| Fenofibrate | Fenofibrate | 226 | 60 |
| Levofloxacin | Levofloxacin | 190 | 127 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 185 | 38 |
| Prednisone | Prednisone | 177 | 66 |
| Sulindac | Sulindac | 177 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 55 |
| Trazodone Hcl | Trazodone Hcl | 165 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 159 | 82 |
| Lisinopril | Lisinopril | 156 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 151 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 37 |
| Leflunomide | Leflunomide | 142 | 32 |
| Nabumetone | Nabumetone | 125 | 36 |
| Fluconazole | Fluconazole | 117 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 43 |
| Metformin Hcl | Metformin Hcl | 105 | 31 |
| Alendronate Sodium | Alendronate Sodium | 102 | 25 |
| Allopurinol | Allopurinol | 99 | 17 |
| Pregabalin | Pregabalin | 97 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 15 |
| Methylprednisolone | Methylprednisolone | 84 | 67 |
| Furosemide | Furosemide | 83 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 83 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 16 |
| Piroxicam | Piroxicam | 76 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 46 |
| Folic Acid | Folic Acid | 74 | 14 |
| Repatha Sureclick | Evolocumab | 74 | 19 |
| Sertraline Hcl | Sertraline Hcl | 74 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 24 |
| Baclofen | Baclofen | 67 | 22 |
| Losartan Potassium | Losartan Potassium | 67 | 17 |
| Simvastatin | Simvastatin | 67 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 15 |
| Azathioprine | Azathioprine | 64 | 17 |
| Glimepiride | Glimepiride | 64 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Atenolol | Atenolol | 57 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 53 | suppressed |
| Klor-Con M20 | Potassium Chloride | 51 | 19 |
| Bumetanide | Bumetanide | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 13 |
| Famotidine | Famotidine | 48 | 11 |
| Sulfasalazine | Sulfasalazine | 48 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Actemra | Tocilizumab | 46 | suppressed |
| Diazepam | Diazepam | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Finasteride | Finasteride | 42 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Humira(Cf) Pen | Adalimumab | 33 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Enbrel Sureclick | Etanercept | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Simponi Aria | Golimumab | 30 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 11 |
| Tymlos | Abaloparatide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Rinvoq | Upadacitinib | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 19 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 16 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Humira Pen | Adalimumab | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Clarithromycin | Clarithromycin | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Niva Thyroid | Thyroid,pork | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | 11 |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,351.99 · 89 records | Amgen Inc. | ACTHAR, BENLYSTA, Bimzelx, COSENTYX, CUTAQUIG, EVENITY, KRYSTEXXA, LEQVIO, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OTEZLA, PANZYGA, PROLIA, PURIFIED CORTROPHIN GEL, REPATHA, RINVOQ, SAPHNELO, TAVNEOS, TREMFYA, UPLIZNA, XELJANZ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rinvoq play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error